A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin

Inclusion Criteria

• •For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
• •At least 18 years of age at screening
• •HbA1c ≥ 8% and ≤ 12% at screening
• •Fasting plasma glucose (FPG) ≤ 270 mg/dL (15mmol/L)
• •Stable dose metformin ≥ 1500 mg per day with or without a stable dose of sulfonylurea (defined as at least 50% maximal dose per local label) for at least 8 weeks
• •estimated glomerular filtration rate (eGFR) \< 60 ml/ml/1.73m2
• •Body Mass Index ≤ 45.0 kg/m2